Loading page…

Report overview

The report says group revenues reached EUR 270 million in 2015, up 22.6%, with strong order intake across its proton-therapy and accelerator businesses. It records 13 new proton-therapy room orders and details the agreement to sell IBA's remaining 40% stake in IBA Molecular, which closed in March 2016. The company also implemented a sustainable-development program to bring its environmental and community commitments into its strategy.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2015
Period: 1 January 2015 – 31 December 2015
Publication date: 21 March 2016
Language
Pages
File size

Standards & Assurance

Standards

Other

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services